Abstract

Somatostatin has direct anti-inflammatory actions and participates in the anti-inflammatory actions of glucocorticoids, but the mechanisms underlying this regulation remain poorly understood. The objective of this study was to evaluate whether somatostatin increases glucocorticoid responsiveness by up-regulating glucocorticoid receptor (GR) expression and signaling. Somatostatin promoted a time- and dose-dependent increase in [(3)H]dexamethasone binding to RAW 264.7 macrophages. Cell exposure to 10 nM somatostatin for 18 h promoted a 2-fold increase in the number of GR sites per cell without significant modification of the affinity. Analysis of GR heterocomplex components demonstrated that somatostatin increased the level of heat shock protein (Hsp) 90, whereas the level of GR remained almost unchanged. The increase in Hsp 90 was associated with a decrease in the cleavage of its carboxyl-terminal domain. Evidence for the involvement of calpain inhibition in this process was obtained by the demonstration that 1) somatostatin induced a dose-dependent decrease in calpain activity and 2) calpain inhibitors, calpain inhibitor I and calpeptin, both abolished the cleavage of Hsp 90 and induced a dose-dependent increase in [(3)H]dexamethasone binding. Increases in glucocorticoid binding after somatostatin treatment were associated with similar increases in the ability of GR to transactivate a minimal promoter containing two glucocorticoid response elements (GRE) and to interfere with the activation of nuclear factor-kappaB (NF-kappaB). Thus, the present findings indicate that somatostatin increases glucocorticoid binding and signaling by limiting the calpain-specific cleavage of GR-associated Hsp 90. This mechanism may represent a novel target for intervention to increase glucocorticoid responsiveness.

Highlights

  • Somatostatin is a cyclic 14-amino acid peptide first isolated from the hypothalamus as a physiological inhibitor of growth hormone secretion [1, 2]

  • In the model of carrageenin-induced acute inflammation, administration of dexamethasone increases the expression of immunoreactive somatostatin in inflammatory cells, whereas administration of anti-somatostatin antiserum prevents the dexamethasone-mediated blockade of leukocyte accumulation [3]

  • Somatostatin Increases Glucocorticoid Binding in the Macrophage Cell Line RAW 264.7—To assess initially the sensitivity of RAW 264.7 cells to somatostatin, these cells were exposed for 24 h to varying concentrations of somatostatin before binding experiments with [3H]dexamethasone were performed

Read more

Summary

Introduction

Somatostatin is a cyclic 14-amino acid peptide first isolated from the hypothalamus as a physiological inhibitor of growth hormone secretion [1, 2]. Somatostatin and preprosomatostatin mRNA have been demonstrated in granuloma cells, mainly macrophages, surrounding parasites in mice infected with Schistosoma mansoni [4]. Such an expression of somatostatin is thought to limit inflammatory processes. We tested the hypothesis that somatostatin increases glucocorticoid responsiveness by up-regulating GR expression. This concept is supported by findings of a direct correlation between the concentration of GR in a target cell and the sensitivity of this cell to glucocorticoids [10]. This increase is not related to an increased expression of GR but represents a stabilization of GR-associated Hsp 90 due to calpain inhibition

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call